date,title,source
Nov-01-18,Aptinyx Completes Enrollment in Phase 2 Study of NYX-2925 for Painful Diabetic Peripheral Neuropathy,GlobeNewswire
Nov-12-18,"Aptinyx Exploratory Clinical Studies Provide First Evidence that NYX-2925 Elicits Rapid, Persistent, NMDAr-Mediated Pharmacodynamic Activity in Humans",GlobeNewswire
Nov-13-18,Aptinyx Reports Third Quarter 2018 Financial Results and Business Highlights,GlobeNewswire
Nov-21-18,"Factors of Influence in 2018, Key Indicators and Opportunity within Atlantic American, Titan Medical, Adial Pharmaceuticals, Aptinyx, Sotherly Hotels, and Titan Pharmaceuticals  New Research Emphasizes Economic Growth",GlobeNewswire
Dec-03-18,Aptinyx Reports Positive Data from Interim Analysis of Exploratory Study of NYX-2925 in Subjects with Fibromyalgia,GlobeNewswire
